NCT01930552View on ClinicalTrials.gov

A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Neoplasm Malignant
Interventions
DRUG

Aflibercept AVE0005

Pharmaceutical form:Solution for infusion Route of administration: Intravenous

DRUG

Leucovorin

Pharmaceutical form:Solution for infusion Route of administration: Intravenous

DRUG

Irinotecan

Pharmaceutical form:Solution for infusion Route of administration: Intravenous

DRUG

5-Fluorouracil

Pharmaceutical form:Solution for infusion Route of administration: Intravenous

Trial Locations (2)

100071

Investigational Site Number 156002, Beijing

510060

Investigational Site Number 156001, Guangzhou

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY

NCT01930552 - A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies | Biotech Hunter | Biotech Hunter